ARN2966(2-PMAP)

  Cat. No.:  DC9345   Featured
Chemical Structure
102212-26-0
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
ARN2966 is a potent post-transcriptional modulator of APP expression; reduces expression of APP with resultant lower production of Aβ.
Cas No.: 102212-26-0
Chemical Name: Phenol, 2-[(2-pyridinylmethyl)amino]-
Synonyms: Phenol, 2-[(2-pyridinylmethyl)amino]-;ARN2966;ARN-2966;(2-Pyridylmethyl)(2-hydroxyphenyl)amine;2-N-(2-Pyridylmethyl)aminophenol;(2-Hydroxyphenyl)(2-pyridylmethyl)amine;2-[(2-Pyridinylmethyl)amino]-phenol;2-[(2-Pyridinylmethyl)amino]-phenol; (2-Hydroxyphenyl)(2-pyridylmethyl)amine
SMILES: OC1=CC=CC=C1NCC2=NC=CC=C2
Formula: C12H12N2O
M.Wt: 200.23648
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: ARN2966 is a potent post-transcriptional modulator of APP expression; reduces expression of APP with resultant lower production of Aβ.
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
2018-0101
Cat. No. Product name Field of application
DC10289 PE859 PE859 is a potent inhibitor of both tau and Aβ aggregation with IC50 values of 0.66 and 1.2 μM, respectively.
DC7645 TH-237A TH-237A(meso-GS 164) is a novel neuroprotective agent exhibiting favorable permeation across the blood brain barrier.
DC8720 FPS-ZM1 FPS-ZM1 is a blood-brain-barrier permeant blocker of RAGE V domain-mediated ligand binding (Ki = 25, 148, & 230 nM, respectively.
DC10506 CPHPC(Miridesap) CPHPC(GSK2315698,Miridesap) is a divalent crosslinker of SAP that causes rapid depletion of circulating SAP via hepatic clearance.
DC9345 ARN2966(2-PMAP) ARN2966 is a potent post-transcriptional modulator of APP expression; reduces expression of APP with resultant lower production of Aβ.
X